Literature DB >> 9455807

High expression of alpha-1-6 fucosyltransferase during rat hepatocarcinogenesis.

K Noda1, E Miyoshi, N Uozumi, C X Gao, K Suzuki, N Hayashi, M Hori, N Taniguchi.   

Abstract

Alpha-1-6 fucosylated alpha-fetoprotein (AFP) is known to be elevated in patients with primary hepatoma and has been suggested as being useful as an early indicator and predictor of the poor prognosis for hepatoma. Although GDP-L-fucosyl-N-acetyl-beta-D-glucosaminide alpha-1-6 fucosyltransferase (alpha-1-6 FucT), is the key enzyme involved in alpha-1-6 fucosylation of AFP, when and how the expression of alpha-1-6 FucT is enhanced during hepatocarcinogenesis is unknown. Recently, we established a convenient assay method for this enzyme and were successful in the purification and cDNA cloning of alpha-1-6 FucT from human gastric cancer, as well as from porcine brain. In the present study, levels of alpha-1-6 FucT activity and mRNA expression have been determined during hepatocarcinogenesis in LEC rats which spontaneously develop hereditary hepatitis and hepatoma. The fetal liver contained the highest enzymatic activity, which tended to increase in inverse proportion to gestation. The enzymatic activity was significantly increased in hepatoma tissues as compared with uninvolved adjacent tissues. Northern-blot analysis revealed high expression of alpha-1-6 FucT mRNA in hepatoma tissues, whereas the expression was fairly low in normal, hepatitis and uninvolved adjacent liver tissues. While the fetal liver had the highest enzymatic activity, the expression of alpha-1-6 FucT mRNA was low, suggesting that another alpha-1-6 FucT is induced in fetal liver or that post-translational modification occurs. High expression of alpha-1-6 FucT was also observed in 3'-MeDAB-induced rat hepatomas and some rat hepatoma cell lines. Collectively, alpha-1-6 FucT was strongly enhanced from an early stage of hepatocarcinogenesis and was maintained at a high level in rat hepatomas.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9455807     DOI: 10.1002/(sici)1097-0215(19980130)75:3<444::aid-ijc19>3.0.co;2-8

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  13 in total

Review 1.  The alpha-L-fucosidase from Sulfolobus solfataricus.

Authors:  Beatrice Cobucci-Ponzano; Fiorella Conte; Mosè Rossi; Marco Moracci
Journal:  Extremophiles       Date:  2007-08-09       Impact factor: 2.395

2.  Fucosylation and gastrointestinal cancer.

Authors:  Kenta Moriwaki; Eiji Miyoshi
Journal:  World J Hepatol       Date:  2010-04-27

3.  Increased levels of tetra-antennary N-linked glycan but not core fucosylation are associated with hepatocellular carcinoma tissue.

Authors:  Anand Mehta; Pamela Norton; Hongyan Liang; Mary Ann Comunale; Mengjun Wang; Lucy Rodemich-Betesh; Alex Koszycki; Katsuhisa Noda; Eiji Miyoshi; Timothy Block
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-04-06       Impact factor: 4.254

Review 4.  Glycosylation in cancer: its application as a biomarker and recent advances of analytical techniques.

Authors:  Yoshimi Haga; Koji Ueda
Journal:  Glycoconj J       Date:  2022-02-14       Impact factor: 2.916

5.  Integrated Proteomic and Glycoproteomic Analyses of Prostate Cancer Cells Reveal Glycoprotein Alteration in Protein Abundance and Glycosylation.

Authors:  Punit Shah; Xiangchun Wang; Weiming Yang; Shadi Toghi Eshghi; Shisheng Sun; Naseruddin Hoti; Lijun Chen; Shuang Yang; Jered Pasay; Abby Rubin; Hui Zhang
Journal:  Mol Cell Proteomics       Date:  2015-08-09       Impact factor: 5.911

Review 6.  Glycosylation Changes in Brain Cancer.

Authors:  Lucas Veillon; Christina Fakih; Hadi Abou-El-Hassan; Firas Kobeissy; Yehia Mechref
Journal:  ACS Chem Neurosci       Date:  2017-11-07       Impact factor: 4.418

7.  Optimisation of the cellular metabolism of glycosylation for recombinant proteins produced by Mammalian cell systems.

Authors:  M Butler
Journal:  Cytotechnology       Date:  2006-06-09       Impact factor: 2.058

8.  Aberrant glycosylation associated with enzymes as cancer biomarkers.

Authors:  Danni L Meany; Daniel W Chan
Journal:  Clin Proteomics       Date:  2011-06-03       Impact factor: 3.988

Review 9.  Enzymes for N-Glycan Branching and Their Genetic and Nongenetic Regulation in Cancer.

Authors:  Yasuhiko Kizuka; Naoyuki Taniguchi
Journal:  Biomolecules       Date:  2016-04-28

Review 10.  Improving Immunotherapy Through Glycodesign.

Authors:  Matthew J Buettner; Sagar R Shah; Christopher T Saeui; Ryan Ariss; Kevin J Yarema
Journal:  Front Immunol       Date:  2018-11-02       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.